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Background: Numerous studies have reported a beneﬁcial impact of neural progenitor cell
transplantation on functional outcome after traumatic brain injury (TBI) during short and
medium follow-up periods. However, our knowledge regarding long-term functional effects
is fragmentary while a direct comparison between local and systemic transplantation is
missing so far.
Objectives:This study investigated the long-term (12week) impact of human fetal neuronal
progenitor cell (hNPC) transplantation 24 h after severe TBI in rats.
Methods: Cells were either transplanted stereotactically (1 × 105) into the putamen or
systemically (5 × 105) via the tail vein. Control animals received intravenous transplantation
of vehicle solution.
Results: An overall functional beneﬁt was observed after systemic, but not local hNPC
transplantation by area under the curve analysis (p < 0.01). Surprisingly, this effect
vanished during later stages after TBI with all groups exhibiting comparable functional
outcomes 84 days after TBI. Investigation of cell-mediated inﬂammatory processes
revealed increasing microglial activation and macrophage presence during these stages,
whichwas statistically signiﬁcant after systemic cell administration (p < 0.05). Intracerebral
hNPC transplantation slightly diminished astrogliosis in perilesional areas (p < 0.01), but
did not translate into a permanent functional beneﬁt. No signiﬁcant effects on angiogenesis
were observed among the groups.
Conclusion: Our results suggest the careful long-term assessment of cell therapies for
TBI, as well as to identify potential long-term detrimental effects of such therapies before
moving on to clinical trials. Moreover, immunosuppressive protocols, though widely used,
should be rigorously assessed for their applicability in the respective setup.
Keywords: neural progenitor cells, cell therapy,TBI, long-term functional outcome, translational research
INTRODUCTION
Acute traumatic brain injury (TBI) is followed by a complex
cascade of pathophysiological sequelae such as excitotoxicity, for-
mation of free radicals, release of inﬂammatory molecules, as well
as diffuse axonal and neuronal injury. These processes exacerbate
blood–brain barrier (BBB) breakdown, activate micro-(Napoli
and Neumann, 2009) and astroglia (Silver and Miller, 2004) and
enhance leukocyte migration to the lesion site, thus ultimately
cumulating into subacute (“secondary”) brain damage (McIntosh
et al., 1996; Teasdale and Graham, 1998) with a net loss of cerebral
tissue and function.
However, regenerative processes parallel the emerging tis-
sue damage. Glial cells were shown (i) to limit expansion of
brain damage by forming a glial scar, (ii) to partly restore the
BBB (Stichel and Müller, 1998; Smith, 2003), (iii) to remove
cell debris and apoptotic cells (Napoli and Neumann, 2009;
Walter and Neumann, 2009), (iv) to control the adaptive immune
system by inﬂuencing antigen presentation (Mrass and Weninger,
2006), and (v) to exert neuroprotective and -restorative effects
(Napoli and Neumann, 2009) such as angiogenesis (Xiong et al.,
2010). Interestingly, endogenous neurogenesis (Gage, 2000) may
be of limited relevance for recovery. Neuronal precursor prolifer-
ation is promoted after TBI, but it is still uncertain whether this
results in stable or functionally relevant neurogenesis (Richardson
et al., 2010; Gao and Chen, 2013).
Anti- and pro-regenerative phenomena seem to be closely
linked on a molecular and cellular level while occurring simulta-
neously over days and even weeks after the initial insult. This pro-
vides a promising opportunity for novel therapeutic approaches
aiming to shift these processes in favor of neuroprotective
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and/or - regenerative mechanisms. Particularly, the paucity of
endogenous restorative capacity may be compensated by local
transplantation of neural stem and progenitor cells. These might
contribute to cell replacement, but tissue restoration by functional
engraftment and its impact are discussed controversely (Kernie
and Parent, 2010). However, the cells were clearly shown to exert
modulatory and supportive (“bystander”) functions such as angio-
as well as neurogenesis (Lu et al., 2003; Gao et al., 2006), and to
modulate microglial (Mosher et al., 2012) as well as T-cell reactiv-
ity (Wang et al., 2009) – a possible key element for functional and
structural brain repair (Kokaia et al., 2012). Although partially
abolished after TBI, the immune-privileged state of the central
nervous system (CNS) in means of both, innate and adaptive
immune responses (Carson et al., 2006), is considered a favorable
environment for cells transplanted to support endogenous repair
processes.
Nevertheless, transplantation experiments addressing the ther-
apeutic potency of a particular stem cell population need to
take into account the clinical situation in terms of the applied
transplantation paradigm, relevant endpoint measurements as
well as the overall examination period. Particularly, the major-
ity of studies investigated the therapeutic beneﬁt in short- (up
to 2 weeks) or medium-term (2–6 weeks) observation peri-
ods [for overview see (Schouten et al., 2004; Harting et al.,
2008)], while our knowledge regarding long-term (6–12 or
more weeks) therapeutic impact of cell therapies is limited to
rare studies focusing on bone marrow mesenchymal (Mahmood
et al., 2005, 2006) and neural progenitor cell (NPC) popu-
lations (Skardelly et al., 2011; Riess et al., 2002). This is of
particular importance since long-term functional outcome may
signiﬁcantly differ from that observed during shorter surveil-
lance periods as reported for experimental treatment approaches
after stroke (Ji et al., 2009) and Parkinson’s disease (Yang et al.,
2009).
Consequently, this study was designed to assess the therapeu-
tic potency of human fetal NPCs after TBI for up to 12 weeks,
as well as to evaluate the inﬂuence of systemic and local NPC
transplantation on post-traumatic functional regeneration, glial
activity, immigration of inﬂammatory cells, and vascularization at
different time points.
MATERIALS AND METHODS
CELL CULTURE
Human fetalNPC (hNPCs; providedbyProf. Dr. Schwarz,Depart-
ment of Neurology, University Clinic of Leipzig, Germany) were
grown and prepared for transplantation. For a pilot hNPC track-
ing study, cells were stained with the red ﬂuorescent in vivo marker
TAMRA (20mM;Sigma–Aldrich) according to themanufacturer’s
instructions prior to administration. For the experimental main
series, cells were not labeled with a ﬂuorescence dye, but identiﬁed
with a human-speciﬁc antibody.
Cells were grown to adherence in cell culture ﬂasks at 37◦C
in 5% CO2 and 5% O2. Growth medium contained 2% B-27
supplement (without vitamin A; Invitrogen, Darmstadt, Ger-
many), recombinant human basic ﬁbroblastic as well as epider-
mal growth factor (both 20 ng/mL; PeproTech, London, UK),
and gentamicin (10 mg/mL; Bio-chrom AG, Berlin, Germany)
in DMEM-F12. Poly-L-ornithine (15 mg/mL; Sigma-Aldrich,
Steinheim, Germany) and human plasma ﬁbronectin (4 mg/mL;
Millipore, Taunus, Germany) were used for coating cell culture
ﬂasks. Every 7 days cells were passaged by incubation with Accu-
tase® (PAA Laboratories, Pasching, Austria) at 4◦C for 10 min
and reseeded at a density of 2.5 × 104 cells/cm2. Cells were
dissociated with Accutase® and assessed for viability by the
trypan blue exclusion method prior to transplantation. Only
samples with > 90% viable cells were used. The desired num-
bers of viable cells (1 × 105 for local and 5 × 105 for systemic
transplantation, respectively) were dissolved in PBS immedi-
ately before local and systemic administration. TAMRA staining
was performed according to manufacturer’s (Sigma Aldrich)
instructions.
ANIMALS AND EXPERIMENTAL GROUPS
All animal experimentswere authorized by the responsible govern-
mental authorities (license number 26/04). Male Sprague-Dawley
rats (n = 72) weighing 280–320 g were kept under a 12 h-light–
dark cycle at constant humidity and temperature with free access
to food and water. All animals received an antibiotic prophy-
laxis with chloramphenicol (75 mg/kg/day, dissolved in drinking
water), starting immediately after TBI. Immunosuppressive treat-
ment [subcutaneous cyclosporine A (CsA), 10 mg/kg; Novartis,
Basel, Switzerland] was initiated after TBI in all animals and
maintained throughout the study.
The pilot cell tracking study was conducted in six animals,
which were allocated to either local or systemic transplanta-
tion (see below) of TAMRA-stained hNPCs 24 h after TBI
(n = 3 each). Rats were sacriﬁced another 24 h later and
immunohistochemically examined for graft detection.
The remaining rats (n = 66) were randomly assigned to three
experimental groups (n = 22 each): controls, systemic (5 × 105
cells) and local transplantation (1 × 105 cells). Each group was
randomly split into four subgroups for immunohistochemical
investigation at 3, 7, 28 (n = 4 each) and 84 days (n = 10) after
TBI according to Figure 1. Weight of all animals was recorded
at the day of surgery and mortality rates were recorded for all
groups.
TRAUMATIC BRAIN INJURY AND CELL TRANSPLANTATION
Traumatic brain injury was induced by controlled cortical impact
(CCI) and cell administration was performed 24 h after injury.
Prior to each surgical intervention rats were anesthetized by
an intramuscular injection of fentanyl (0.005 mg/kg; Ratio-
pharm, Germany), midazolam (2 mg/kg; Ratiopharm, Ulm,
Germany) and medetomidine (0.15 mg/kg; Orion Pharma, Ham-
burg, Germany). Body temperature was kept at 37◦C during
surgery using a feedback-controlled heating pad equipped with
a thermistor rectal probe (FHC Inc., USA). Brieﬂy, the rat’s
head was shaved and placed in a stereotaxic frame. The ﬁeld
for surgery was cleaned with Betaseptic® (Braun, Melsungen,
Germany) before exposition of the skull bone by midline skin
incision. A round craniotomy (7 mm) was performed 3.5 mm
lateral to Bregma on the left side. TBI was induced by CCI
using an electromagnetically controlled piston (5 mm; Cus-
tom Design and Fabrication, Virginia Commonwealth University,
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FIGURE 1 | Outline of the experimental design. (A) provides a
scheme drawing illustrating the experimental plan. “Tx” indicates
transplantation time points while the cross sign indicates time points of
animal sacriﬁce. A representative image of the lesion after experimental
TBI is given in (B) and areas investigated during histological
assessments are indicated in (C). BZ, border zone; Tr, trauma; CC,
corpus callosum; Co, perilesional cortex; BG, basal ganglia. Scale bar
represents 200 μm.
Richmond, VA, USA), which was placed perpendicularly above
the exposed, but intact meninges. The device was calibrated to
a impact speed of 4 m/s and a compression of 2.5 mm over
150 ms. Following surgery and skin wound suture, anesthe-
sia was antagonized using naloxone (0.12 mg/kg; Ratiopharm),
ﬂumazenil (0.2 mg/kg; Hoffmann-La Roche, Basel, Switzerland)
and atipamezole (0.75 mg/kg; Orion Pharma). The overall study
design and a typical lesion example following TBI are given in
Figures 1A,B.
Rats assigned to local hNPC transplantation were re-
anaesthetized and placed in a stereotactic frame. A deposit
containing 1 × 105 cells (passage 8–12, in 3 μL PBS) and located
3 mm beneath the meningeal layer was placed through the cen-
ter of the contusion using a 26-gage needle connected to a 10 μL
Hamilton syringe. After gentle cell injection over 6 min, the needle
was slowly withdrawn over further 4 min. For systemic transplan-
tation and control purposes, animals received 500μL of either cell
suspension (5 × 105 hNPCs, passage 8–12) or PBS via the tail vein.
FUNCTIONAL TESTS
The modiﬁed neurological severity score (mNSS) comprises
14 single items that evaluate motor and sensory function, as
well as balance and reﬂexes (Ji et al., 2009). The test is widely
to assess therapeutic impact of experimental procedures after
brain injury. The rotarod test is a reliable tool to follow up
and evaluate motor function after TBI in rodents (Ji et al.,
2009). The rats were placed on a computer-controlled accel-
erating rotating rod (TSE Systems, Bad Homburg, Germany).
The time before dropping off the rod (latency) was measured
ﬁve times for each rat and latency mean values were recorded
for each day. All animals were trained on the rotarod for
2 weeks before baseline latencies were measured 1 day prior
to TBI.
The rotarod test were conducted in the long-term subgroups
(n = 10 each) at days -1, 2, 4, 8, 14, 21, 28, 42, 49, 56, 63,
70, 77, and 84 after TBI after appropriate training. The modiﬁed
Neurological Severity Score (mNSS) was performed at day -1, 2,
8, 14, 28, 42, and 84. All investigators were blinded to group
allocation.
IMMUNOHISTOCHEMICAL STAINING AND ANALYSIS
Tissue preparation
Rats allocated to immunohistochemical analysis were euthanized
by an intraperitoneal injection of xylazine (50 mg/kg; Bayer
AG, Berlin, Germany) and ketamine (200 mg/kg; Merial, Hal-
bergmoos, Germany) at 24 h (cell tracking pilot study), 3, 7,
28, and 84 days following TBI. After thoracotomy, animals were
perfused transcardially with 50 mL ice-cold heparinized PBS, fol-
lowed by 250 mL 4% paraformaldehyde (PFA) in 0.1 M PBS
using an automatic perfusion pump (Braun, Melsungen, Ger-
many). The brains were gently removed and stored in 4% PFA
in 1 M PBS for 4 h before being equilibrated in 30% sucrose
at 4◦C for 48 h. A 1 cm coronal block engulﬁng the entire
trauma region was then cut from each brain and placed in
embedding medium (OCT, Sakura Finetek, Germany), frozen
in liquid nitrogen-cooled isopentane and kept at –80◦C. Whole
blocks were cut into 40 μm coronal sections using a cryotome.
The slices were stored in an antifreeze solution (30% glycerol,
30% ethylene glycol, 40% aqua bidest, 13 mM monosodium
phosphate, and 39 mM disodium phosphate) at −20◦C until
staining.
Tissue staining
All histochemical stainingswere performed on 40μmfree-ﬂoating
coronal sections using appropriate primary antibodies according
to Table 1. The streptavidin-biotin immunoperoxidase staining
method was utilized for visualization in all cases.
For detection of the graft after local and systemic transplan-
tation brain slices were stained with HuNu, an antibody being
speciﬁc for human nuclei, and further screened for TAMRA
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Table 1 | Antibodies used in immunohistochemistry.
Antigen Target Source Dilution Company and clone
CD11b (Ox42) Microglia Mouse 1:200 Chemicon, CBL 1512
CD68 (ED1) Macrophages Mouse 1.250 Chemicon, MAB1435
GFAP Astroglia Mouse 1:400 Sigma, G3893
HuNu Human Cells Mouse 1:100 Chemicon, MAB1281
NeuN Neurons Mouse 1:200 Chemicon, MAB377
RECA Vessels Mouse 1:250 Serotec, MCA970R
Streptavidin – 1:100 Invitrogen
staining. In vitro-preparation (smears) of hNPCs served as a
positive control for human nuclei (HuNu) staining.
Immunohistochemical analyses
Brain specimens were assessed semi-quantitatively by light
microscopy. For post-processing, Olympus’ (New York, NY, USA)
ANALYSIS program was used. Five sections with an intersec-
tional distance of 800 μm, and encompassing the center of
the brain injury, were evaluated for each animal. Regions of
interest (Figure 1C) were investigated by counting of positive
events in one ﬁeld of view (FOV) at 40x magniﬁcation. Astro-
and microglial/macrophage reactivity in the contusion border
zone (BZ), traumatic cortical areas directly below the contusion
(trauma, Tr), the perilesional cortex (Co), corpus callosum (CC),
and basal ganglia (BG, see Figure 1C for localization details) were
investigated applying a semi-quantitative neuropathological score
(Table 2).
Additionally, neuronal (NeuN) and vascular (RECA) com-
partments were analyzed in the BZ laterally and medially to the
lesion as well as in ipsilateral cortical areas. To this end, cap-
turedmicrographswere converted to binary images (white: stained
areas/black: unstained areas). The area of positive structures on the
lesioned (ipsilateral) side expressed as percentages and compared
between groups (Figure 2).
Statistical analysis
All data are depicted as mean ± SD. Behavioral data were cal-
culated as percent of d-1 for the rotarod test and derivation to
d-1 for the mNSS, respectively. Data obtained at d-1, d2, and
d84 were assessed by one-way analysis of variance (ANOVA)
or ANOVA on ranks (in case of not normally distributed data)
Table 2 | Grading of microglial and astroglial reaction assessed by
expression of CD11b and CD68.
Grade CD11b/GFAP CD68
0 No reaction 0 pos. cells
1 Slight reaction <10 pos. cells
2 Moderate reaction 10–50 pos. cells
3 Strong reaction 50–200 pos. cells
4 Very strong reaction >200 pos. cells
while development of functional impairment over the observa-
tion period was investigated by standard area under the curve
(AUC) analysis. All histological data were analyzed using one-way
ANOVA or ANOVA on ranks tests. The Holm–Sidak method was
applied for post hoc pairwise multiple comparison procedures;
Dunn’s test was used for not normally distributed data. All
procedures were performed using the SigmaPlot 11.0 software
package (Systat Software, Chicago, IL, USA). Levels of statisti-
cal signiﬁcance are indicated by single (∗p < 0.05) or double
(∗∗p < 0.01) asterisks. Due to small sample sizes and thereby
limited statistical power, histological data from days 3, 7, and
28 were not subjected to statistical analysis, but only described
qualitatively.
RESULTS
PILOT STUDY FOR GRAFT IDENTIFICATION
In a pilot cell detection study, presence of transplanted cell at
the lesion site 24 h after local and systemic transplantation was
indicated by the TAMRA signal. In animals subjected to local
transplantation, numerous TAMRA+ cells were detected in the
putamen and in the vicinity of the injection canal (n = 3/3). After
systemic transplantation, many TAMRA+ cells were identiﬁed in
the border zone with only a few, scattered cells in the contusion
area (n = 3/3, see Figure 3).
GENERAL ASPECTS OF TREATMENT SAFETY
We did not observe general signs for safety concerns being related
to both treatment procedures, especially no mortality in all
groups.
Functional outcome
There were no statistically signiﬁcant differences in performance
for both behavioral tests among groups in the rotarod and mNSS
tests before TBI (d-1, p > 0.4, data not shown). Behavioral phe-
notyping was not possible 24 h after TBI and immediately before
hNPC treatment because of signiﬁcant affection of animals by
trauma, which prevented reliable functional assessments. How-
ever, no differences were observed between control and systemic
transplantation groups at d2 and d4 post TBI in the rotarod
(p > 0.4 and p > 0.1, Figure 4A) and at d2 in the mNSS test
(p > 0.2, Figure 4C), arguing against inter-group differences
directly after trauma induction.
Expectedly, animals receiving local hNPC transplantation
showed lowest mean values in the rotarod and highest scores in the
mNSS,butwithout reaching statistical signiﬁcance (p>0.05) 1day
after transplantation. This was likely due to the second surgical
intervention conducted for local transplantation.
Although slight improvements from baseline values (d2) were
observed in locally transplanted animals (p > 0.05), rotarod per-
formance did not improve markedly in those animals and controls
during the observation period. Systemically transplanted animals
showed an overall superior performance as compared to local
transplantation and control groups (p < 0.01, Figure 4B). How-
ever, the therapeutic beneﬁt was only transient and all groups
showed a comparative rotarod performance between 38 (local
transplantation) and 43% (systemic transplantation) of pre-lesion
baseline values on d84 (p > 0.4).
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FIGURE 2 | Determination of vascular changes by RECA. Demonstration of
the vascular reaction by the panvascular marker RECA-1 (rat endothelial cell
antigen) 3 days after brain injury. (A,B) show an overview of the ipsilateral (A)
and contralateral (B) side of a systemically transplanted animal. Images are
acquired by fusion of 9 single images of 2.5x magniﬁcation. (C,D)
demonstrate the same images after binary transformation. (E–H) show the
lateral (E) and medial (F) border zone at high power and corresponding
contralateral regions (G,H). The RECA-positive proportions are indicated as
percentages exhibiting an induction of RECA-expression after brain injury and
transplantation (E–H).
FIGURE 3 | Cell tracking withTAMRA 24 h after hNPC transplantation.
Fluorescent images of brain slices 24 h after systemic (A–C) and local (D–F)
transplantation of TAMRA-stained human fetal neuronal progenitor cells. Cell
nuclei are displayed in blue (DAPI) and TAMRA positive cells in red. (A–C):
The left side of images shows the impact area with rareﬁed cell density. In
the center one can identify the border zone with many inﬁltrated
TAMRA-positive cells and on the right side the adjacent unharmed cortex.
(D–F): The images display the injection canal with multiple surrounding
TAMRA-positive cells. In higher magniﬁcation (x100) one can identify single
cells and their nuclei.
In accordance to the rotarod test, there was no statistically sig-
niﬁcant mNSS score difference between the groups at d2 and d84
post transplantation (p > 0.1 and p > 0.4, Figure 4C). Although
lowestmeanmNSS scoreswere observed after systemic andhighest
after local transplantation, there was no statistically signiﬁcant
difference in overall performance among the groups (p > 0.1,
Figure 4D).
Histological analysis and cell tracking
In contrast to results of the graft identiﬁcation pilot study,
hNPCs could not be detected after either local or systemic
transplantation by the human nuclei antibody (huNu) at any
later investigated time-points after d3, although the positive
smear control conﬁrmed the functioning of the antibody in every
case.
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FIGURE 4 | Behavioral phenotyping after hNPC transplantation. In the
rotarod test, animals subjected to systemic cell transplantation showed a
superior performance particularly in the middle of the observation period
(A). Despite the functional beneﬁt was transient, it translated into an
overall therapeutic effect as indicated by AUC analysis (B). No statistically
signiﬁcant therapeutic effect was observed in the mNSS test although
systemically transplanted subjects showed lowest mean AUC values (C,D).
**p < 0.01.
FIGURE 5 | Changes in the neuronal and vascular compartments after
hNPC transplantation. All information is given in average area
percentages of positive staining in investigated micrographs. Higher
numbers of NeuN+ cells were observed 3 days after local hNPC
transplantation (A), but not thereafter. At day 84, animals receiving
systemic or local cell transplantation presented lowest density of NeuN+
cells in the lesion border zone (B). Despite highest mean density of
RECA+ cells at day 84 after local transplantation, there was no
statistically signiﬁcant intergroup difference in vascularization (C–F).
*p < 0.05.
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FIGURE 6 | Macrophage and microglia activity after hNPC
transplantation. Macrophage density as indicated by CD68 staining was
increased at all investigated time points in animals receiving local or
systemic hNPC transplantation (A–D). Statistically signiﬁcant differences
were observed at 84 days after systemic cell transplantation in the area of
the trauma, the corpus callosum and the basal ganglia (B,D). A similar
picture was observed for CD11b microglia. Apart from basal ganglia at early
stages, highest mean numbers of these cells were observed at all
investigated time points in both treatment groups (E,F). Signiﬁcantly
enhanced numbers of microglia were detected 84 days after systemic cell
transplantation in the perilesional cortex and the basal ganglia (F).
*p < 0.05.
Neuronal and vascular compartments
At day 3 after hNPC transplantation, slightly higher NeuN density
was observed in locally transplanted subjects. While no obvious
differences were observed at days 7 and 28, a reduced density of
NeuN-positive cells was observed at day 84 in both, the locally and
systemically transplanted subjects (p < 0.05 each).
Transplantationof hNPCslightly increasedRECAexpression in
comparison to control conditions with higher mean percentage of
RECA+ structures being observed in both transplantation groups
and at any investigated time point in the BZ and cortical areas
(Figures 5C–F). Most RECA+ vessels were seen in animals sub-
jected to local transplantation. However, statistically signiﬁcant
differences among the groups were not detected at d84 (p > 0.05,
Figure 5D).
Impact of cell transplantation on macrophages and microglial
activity
CD68 (ED1) and CD11b (Ox42) antibodies recognizing microglia
and macrophages were used to assess neuroimmunological
reactions after therapeutic cell transplantation (Figure 6).
Treated animals showed higher amounts of CD68-positive
macrophages in corpus callosum, basal ganglia and trauma-
affected cortical areas (Figures 6A,C). At d84, this differ-
ence was statistically signiﬁcant for animals receiving systemic
transplantation (p < 0.05 each, Figures 6B,D, for overview
see also Figure 7). In contrast, no major differences were
observed in the perilesional cortex with the number of CD68
cells slightly decreasing from d3 and/or d7 values toward d84
(Figures 6C,D).
Assessment of microglial reactivity (CD11b+) revealed inter-
regional differences at d3 following TBI (Figure 6E). At d7, most
pronounced microglial activation was observed after local hNPC
transplantation in the cortex and corpus callosum (Figure 6E,
for overview see also Figure 8). During later stages, this picture
changed to higher CD11b expression in animals receiving systemic
cell transplantation. In this group, differences were statistically
signiﬁcant in the perilesional cortex and basal ganglia (p < 0.05,
Figure 6F) with highest density of CD11b cells being observed in
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FIGURE 7 | Overview of macrophage activity (CD68) 84 days after
hNPC transplantation. photomicrographs depicting inﬁltration of CD68
positive cells of one animal of each group 84 days after brain injury and
transplantation. Overview images are acquired by fusion of 9 single
images of 2.5x magniﬁcation. Control group (A–C), local transplantation
(D–F) and systemic transplantation (G–I). Insets of higher magniﬁcation
(scale bars = 40 μm) on the right upper part of each image reveal
details of the single cells. It is obvious that the systemically transplanted
show the highest number of CD68 positive cells and the control the
lowest.
all assessed regions. Unfortunately, analysis of the corpus callosum
was confounded by a technical incident rendering the majority of
samples from d84 after local transplantation (n = 7/10) unfeasible
for analysis.
Impact of cell transplantation on post-traumatic astrogliosis
Analysis of reactive gliosis revealed a highly heterogenous pattern
between different locations and groups. In general, astrogliosis
was most pronounced in areas next to the lesion such as the per-
ilesional cortex and the lesion border zone (Figures 9A,C), but
surprisingly not cortical areas directly affected by TBI (Figure 9A).
Local hNPC-transplantation signiﬁcantly reduced astrogliosis in
the border zone at day 84 (p < 0.01, Figure 9B). This result was
not replicated in other investigated regions at day 84 (p > 0.05,
Figure 9D), while astrogliosis was indifferent in the cortical areas
affected by the trauma (p > 0.4, Figure 9A)
DISCUSSION
This study was designed to evaluate the long-term impact of
hNPC transplantation on the functional outcome after TBI,
comparing intracerebral (stereotaxic) and intravenous trans-
plantation paradigm. The cells were transplanted in the sub-
acute stage 24 h after brain injury. This early time-point was
chosen to take advantage of potential neuroprotective effects
mediated by the graft, knowing that cell survival and via-
bility would be likely more compromised in the subacute
than in a chronic stage after TBI. Immunosuppression was
started immediately thereafter mimicking a potential clini-
cal scenario. Sustained functional improvement has not been
detected after either transplantation approach although systemic
NPC administration was associated with a transient functional
improvement. No histological signs for a therapeutic modula-
tion or cell replacement have been observed. However, some
evidence was collected for ongoing inﬂammatory responses in
the brain potentially leading to graft rejection and/or addi-
tional tissue damage despite the continuous immunosuppression
by CsA.
SAFETY ASPECTS OF NPC TRANSPLANTATION AND ASSESSMENT OF
ADMINISTRATION ROUTES
Both treatment paradigms were safe without signiﬁcantly
enhanced mortality or reduced functional outcome among
groups. However, individual performance was lowest during the
early observation period after local transplantation. Although
stereotaxic administration allows accurate placement of stem or
progenitor cells in the target region and may, potentially, lead to
higher concentrations of therapeutic cells and thereby enhanced
cellular restoration, we did not found evidence for any of such
processes in our study. However, the surgical intervention may
have caused some transient but additional impairment without
improved long-term outcome, advising caution regarding inva-
sive cell administration procedures at least in the subacute stage
following TBI. In turn, systemically administered hNPC may
get stuck in pulmonary capillaries during the lung passage as
shown for mesenchymal stem cells (MSC; Schrepfer et al., 2007).
The MSC soma diameter (15–19 μm) is signiﬁcantly larger than
the one of murine pulmonary capillaries (5–8 μm; Schrepfer
et al., 2007) and the soma volume of NPCs is comparable to
MSC, exceeding that of circulating mononuclear leukocytes by
an order of magnitude (Fischer et al., 2009). This conﬁrms the
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FIGURE 8 | Overview of microglial activity (CD11b) 7 and 84 days
after local and systemic hNPC transplantation. CD11b stained
photomicrographs of locally and systemically transplanted animals 7 days
and 84 days after transplantation. (A–D) display an overview of a locally
transplanted animal 7 days (A) and 84 days (C) as well as a
systemically transplanted animal 7 days (B) and 84 days (D) after
transplantation. (E–L) depict the border zone beneath the impact area
(E–H) and the corpus callosum with the adjacent cortex and putamen
(I–L). Insets show details of each subgroup at high power (scale
bars = 40 μm).
assumption that cells can be ﬁltered in the pulmonary capillary
bed after systemic administration although a potentially related
adverse effect on pulmonary function is left for further investiga-
tion. Other peripheral organs such as the spleen or the kidneys
may also ﬁlter the systemically administered cells (Fischer et al.,
2009). Interestingly, lower densities of NeuN-positive cells were
observed in both, locally and systemically transplanted subjects
at day 84. This may indicate a delayed immunological reaction
against neuronal cell populations despite immunosuppression,
which may even go beyond xeno-graft removal. This would
also be in line with observed mid- and long-term indications
of immunoreactivity after local and systemic cell transplanta-
tion, respectively. However, the lack of further data renders
this assumption purely speculative and strongly suggests further
investigation.
EFFICACY OF NPC TRANSPLANTATION
Experimental studies using a variety cell types and transplanta-
tion paradigms have shown to improve the functional outcome
following TBI within 2 weeks after cell transplantation (Hart-
ing et al., 2008; Maegele and Schaefer, 2008). Accordingly, we
detected a clear functional improvement after systemic transplan-
tation in the rotarod test with best performance observed during
the medium-term observation period (2–6 weeks). However, this
effect subsequently vanished, what was accompanied by signs
of delayed induction of microglial activation and macrophage
recruitment, both representing hallmarks of neuroinﬂammation
followingTBI (Schwab et al., 2002). No functional beneﬁt by either
transplantation paradigm was evident at 12 weeks, representing
an overall neutral result regarding this clinically decisive outcome
parameter.
MECHANISMS OF CELL BASED FUNCTIONAL IMPROVEMENTS
Many groups were unable to detect any cells at later stages after
local or systemic transplantation. Hence, functional recovery is
unlikely to be explained by cellular restoration. Moreover, there
is evidence that functional improvement is not necessarily related
to cell engraftment (Lu et al., 2002; Harting et al., 2008) and par-
ticularly early functional improvements are more likely explained
by neuroprotective or -modulative inﬂuences. For example, angio-
genesis plays a crucial role during post-traumatic neuroprotection,
in particular by restoring oxygen and nutrient supply and enabling
immune cells to invade the lesion and to remove cell debris (Beck
and Plate, 2009). Angiogenesis can already be detected within
3 days after ischemia and is induced by angiogenic factors such
as VEGF and bFGF, which may even be secreted by cells outside
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FIGURE 9 | Modulation of astrogliosis by hNPC treatment. astroglial
activation patterns showed a heterogenous phenotype. There was a
tendency toward reduced astroglial activity in most investigated areas in
animals receiving local hNPC administration, particularly at days 28 and 84
in trauma and border zones (A,B) as well as the perilesional cortex,
corpus callosum and basal ganglia (C,D). However, this difference was
only statistically signiﬁcant in the lesion border zone at day 84 (B).
**p < 0.01.
the brain (Chen et al., 2005). Although not statistically signiﬁcant,
we observed a slight increase of RECA+ vessels in animals receiv-
ing hNPC transplantation. This was most prominent at d21, but
not at d84 following systemic cell administration. Hence, observed
transient functional improvements may be related to the release
of angiogenic and potentially neurotrophic factors (Lu et al., 2003;
Gao et al., 2006), but were not perpetuated because hNPC admin-
istration did not exert a signiﬁcant long-term effect on cerebral
microvessel density.
NEUROIMMUNOLOGICAL ASPECTS OF LOCAL PROGENITOR CELL
TREATMENT
We observed a signiﬁcant increase of reactive microglia and
macrophages particularly 12 weeks after trauma and transplan-
tation. Although microglia are not primarily antigen presenting
cells, they belong to the monocyte-macrophage system and are
key players within the cerebral innate immune system (Mrass and
Weninger, 2006). After brain injury, microglia become activated
while macrophages are recruited to the brain parenchyma within
24 h. The least favorable functional performance was observed
within the ﬁrst 2 weeks after both TBI and local transplanta-
tion, potentially related to the additional trauma caused by local
cell transplantation. Indeed, CD68+ and CD11b+ cells were
transiently increased between d3 and d7 in most investigated
regions, particularly in those regions situated in the vicinity
of the lesion. Although the brain is considered an immune-
privileged organ in its steady state, a stereotactically implanted
cell graft is located in an immunologically active environment.
FIGURE 10 | Macrophage (CD 68) infiltration around the injection canal
7 days afterTBI. demonstration of the injection canal by CD68 staining
7 days after local transplantation. One can observe a massive local
inﬁltration of CD68 positive cells. On the right the inset displays the tip of
the canal in a higher magniﬁcation to show details of single cells.
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Next to immune stimuli arising from the immediate cell death
and tissue damage, an immunological activation can be triggered
and fostered by BBB disruption, massive inﬁltration of antigen-
presenting cells, an up-regulation of MHC-class II, altogether
promoting recruitment and activation of T-cells and eventu-
ally graft rejection (Holmin and Mathiesen, 1999; Neumann,
2001; Galea et al., 2007). Consequently, it was shown by Shindo
et al. (2006) that the survival rate of the graft highly depends
on micro-environmental conditions with negative correlation to
the severity of trauma and time to transplantation. Potentially,
craft-borne cell debris may represent a strong stimulus to local
microglia and recruited macrophages, also inducing removal
of surviving cells within the graft at later stages. Indeed, we
were not able to detect any transplanted cell but observed a
strong inﬁltration of macrophages around the injection canal
(Figure 10).
Widespread amelioration of astrogliosis was shown to corre-
spond to improved functional outcome after CNS injury (Boltze
et al., 2012). Local transplantation of hNCP induced a long-term
decrease of astrogliosis in the lesion border zone, but not in other
investigated areas. Thus, this effect may be too limited to translate
into a robust therapeutic beneﬁt, particularly in the context of
above-mentioned neuroimmunological sequelae of local hNPC
transplantation.
LIMITATIONS OF THE APPLIED METHODS AND PROTOCOLS
This study comes with a number of limitations arising from
methodological aspects, deserving a critical discussion. In par-
ticular, the failure to detect any surviving cells 84d after trans-
plantation may be related to the applied xenotransplantation
paradigm in combination with insufﬁcient immunosuppres-
sion.
It has been shown independently from our experiments that
NPCs can survive after xenotransplantation in the rodent envi-
ronment under the same immunosuppressive regime and even
without any immunosuppression (Schwarz et al., 2006), which is
believed to be related to the immunological naivety of the cells as
well as immunomodulatory capabilities (Gao et al., 2006; Mosher
et al., 2012). However, the constellation of results obtained in our
study questions this assumption. Ongoing graft rejection or even
host tissue damage may be reﬂected by the overall increased num-
bers of CD68+ andCD11b+, whichwas statistical signiﬁcant after
systemic transplantation (Figure 6), as well as the reduced num-
bers of neuronal cells in transplanted animals (Figure 5) 84 days
after transplantation.
The CsA mode of action is blocking of the nuclear factor of
T cells (NFAT) via calcineurin inhibition. Since NFAT is a key
regulator of pro-inﬂammatory cytokine expression (Kiani et al.,
2000), CsA effectivelymitigates inﬂammatory responses and selec-
tively impairs T cell proliferation (Halloran et al., 1999). However,
local (microglia) and peripheral (monocytes) phagocytotic cells
are unaffected by CsA. It may hence be speculated that the innate
immune system, particularly after BBB breakdown, is sufﬁcient to
eliminate the xenograft. Although stem cell populations can exert
a therapeutic beneﬁt beyond differentiation and functional inte-
gration (Oki et al., 2012), the rejection of the transplant may have
accounted to the overall neutral study results. Further research
should consider this possibility; especially since CsA application is
a very common protocol for immunosuppression in experimental
studies.
CONCLUSION
Our results underscore the fundamental importance of long-term
observation periods during the evaluation of experimental treat-
ment strategies for TBI. Short observations periods may provoke
an over- or underestimation of the therapeutic effect, which
can at least partly be attributed to the extended time course of
CNS lesion pathophysiology and reorganization. In our study, we
would have overestimated the therapeutic effect of hNPC trans-
plantation if the observation was limited to 4–6 weeks, which is
common in experimental studies. Therefore, future studies should
be long enough to reliably depict the pathophysiological steady
state after CNS injury. This conclusion is supported by studies
from other areas of experimental cell therapies for CNS disorders
such as ischemic stroke (Balseanu et al., 2014). On the other hand,
common practice in immunosuppressive treatments may require
careful consideration during the design of such long-term experi-
ments as non-autologous grafts may be subject to rejection despite
implementation of the commonly applied CsA immunosuppres-
sion paradigm. Hence, we suggest not only a thorough evaluation
of clinically relevant endpoints and experimental protocols, but
observation periods being sufﬁcient to reﬂect the ﬁnal outcome of
the disease model in order to detect late effects of any therapeutic
intervention.
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